KR100729887B1 - 알로에로부터 유래된 다당류를 포함하는 조성물 - Google Patents
알로에로부터 유래된 다당류를 포함하는 조성물 Download PDFInfo
- Publication number
- KR100729887B1 KR100729887B1 KR1020067017809A KR20067017809A KR100729887B1 KR 100729887 B1 KR100729887 B1 KR 100729887B1 KR 1020067017809 A KR1020067017809 A KR 1020067017809A KR 20067017809 A KR20067017809 A KR 20067017809A KR 100729887 B1 KR100729887 B1 KR 100729887B1
- Authority
- KR
- South Korea
- Prior art keywords
- immuno
- aloe
- polysaccharides
- polysaccharide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 88
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 88
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 88
- 235000011399 aloe vera Nutrition 0.000 title claims abstract description 67
- 241001116389 Aloe Species 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 14
- 150000002772 monosaccharides Chemical class 0.000 claims description 14
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- 230000007813 immunodeficiency Effects 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 18
- 150000001720 carbohydrates Chemical class 0.000 abstract description 11
- 235000014633 carbohydrates Nutrition 0.000 abstract description 11
- 239000003357 wound healing promoting agent Substances 0.000 abstract description 9
- 239000002955 immunomodulating agent Substances 0.000 abstract description 7
- 229940121354 immunomodulator Drugs 0.000 abstract description 7
- 238000001556 precipitation Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 44
- 239000000499 gel Substances 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 32
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 27
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 27
- 238000001914 filtration Methods 0.000 description 19
- 208000010247 contact dermatitis Diseases 0.000 description 18
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 17
- 108010059892 Cellulase Proteins 0.000 description 16
- 229940106157 cellulase Drugs 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 239000000284 extract Substances 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000005069 ears Anatomy 0.000 description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- 229920005654 Sephadex Polymers 0.000 description 8
- 239000012507 Sephadex™ Substances 0.000 description 8
- 239000003610 charcoal Substances 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000012466 permeate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000003301 hydrolyzing effect Effects 0.000 description 5
- 230000002584 immunomodulator Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 244000186892 Aloe vera Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940003587 aquaphor Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XDIYNQZUNSSENW-KZXKDKCNSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O XDIYNQZUNSSENW-KZXKDKCNSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 229910000619 316 stainless steel Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940006091 aloe polysaccharide Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012857 repacking Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6168197P | 1997-10-10 | 1997-10-10 | |
| US60/061,681 | 1997-10-10 | ||
| US9827198P | 1998-08-28 | 1998-08-28 | |
| US60/098,271 | 1998-08-28 | ||
| KR1020007003894A KR100678238B1 (ko) | 1997-10-10 | 1998-10-09 | 알로에로부터 면역조절성 다당류를 제조하는 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007003894A Division KR100678238B1 (ko) | 1997-10-10 | 1998-10-09 | 알로에로부터 면역조절성 다당류를 제조하는 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20060103285A KR20060103285A (ko) | 2006-09-28 |
| KR100729887B1 true KR100729887B1 (ko) | 2007-06-18 |
Family
ID=26741367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067017809A Expired - Lifetime KR100729887B1 (ko) | 1997-10-10 | 1998-10-09 | 알로에로부터 유래된 다당류를 포함하는 조성물 |
| KR1020007003894A Expired - Lifetime KR100678238B1 (ko) | 1997-10-10 | 1998-10-09 | 알로에로부터 면역조절성 다당류를 제조하는 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007003894A Expired - Lifetime KR100678238B1 (ko) | 1997-10-10 | 1998-10-09 | 알로에로부터 면역조절성 다당류를 제조하는 방법 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US6133440A (enExample) |
| EP (1) | EP1036187A4 (enExample) |
| JP (1) | JP4542262B2 (enExample) |
| KR (2) | KR100729887B1 (enExample) |
| WO (1) | WO1999019505A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030096378A1 (en) * | 1997-10-10 | 2003-05-22 | Univera Pharmaceuticals, Inc. | Process for the preparation of immunomodulatory polysaccharides from aloe |
| US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
| US7196072B2 (en) * | 2000-07-10 | 2007-03-27 | University Of Mississippi | High molecular weight polysaccharide fraction from Aloe vera with immunostimulatory activity |
| US7494669B2 (en) | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| EP1323738A1 (en) * | 2001-12-27 | 2003-07-02 | 2QR Research BV | Negatively charged polysaccharide derivable form Aloe Vera |
| US20050004211A1 (en) * | 2003-06-30 | 2005-01-06 | Kaohsiung Medical University | Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds |
| US7754704B2 (en) | 2004-03-31 | 2010-07-13 | Morinaga Milk Industry Co., Ltd. | Method for treating hyperglycemia |
| KR100743852B1 (ko) | 2004-03-31 | 2007-08-02 | 모리나가 뉴교 가부시키가이샤 | 4-메틸에르고스트-7-엔-3-올 골격을 갖는 글리코사이드 및고혈당 개선제 |
| US7507424B2 (en) * | 2004-04-26 | 2009-03-24 | Mmi Corporation | Natural immunostimulant compositions, methods for obtaining the same and pharmaceutical formulations thereof |
| US7175860B2 (en) * | 2004-08-02 | 2007-02-13 | Haskell Pharmaceuticals, Inc. | Enhanced wound healing method and composition |
| US7410661B2 (en) * | 2004-08-02 | 2008-08-12 | Weston Haskell | Enhanced wound healing method, product and composition |
| JP3924310B2 (ja) | 2004-09-29 | 2007-06-06 | 森永乳業株式会社 | 高血糖改善のための医薬及び飲食品 |
| US20060084629A1 (en) * | 2004-10-15 | 2006-04-20 | Alvin Needleman | Immune system activating formula composed of selected long chain polysaccharides from natural sources |
| RU2353368C1 (ru) | 2005-05-17 | 2009-04-27 | Моринага Милк Индастри Ко., Лтд. | Лекарственное средство и пищевой продукт или напиток для улучшения функций поджелудочной железы |
| CA2584974C (en) | 2005-05-17 | 2010-04-20 | Morinaga Milk Industry Co., Ltd. | Drug and food or drink for improving pancreatic functions |
| US7531520B2 (en) | 2005-05-17 | 2009-05-12 | Morinaga Milk Industry Co., Ltd. | Drug and food or drink for improving pancreatic functions |
| US20070036840A1 (en) * | 2005-07-27 | 2007-02-15 | Jose Antonio Matji Tuduri | Phosphorylated glucomannan polysaccharides containing 1-6 and 1-2 linkages increase weight gain in swine |
| JP4954523B2 (ja) * | 2005-09-26 | 2012-06-20 | 長谷川香料株式会社 | 高濃度のｓ−アルケニル（またはアルキル）システインスルフォキサイド類を含有する抽出物の製造方法 |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN103083642B (zh) * | 2007-05-11 | 2015-11-18 | 芦荟研究实验室公司 | 用于皮肤增强的芦荟制剂 |
| CN101980695B (zh) * | 2008-05-16 | 2013-05-22 | 株式会社日冷生物科学 | 由兰科植物得到的提取物、生产所述提取物的方法和包含所述提取物的皮肤外用剂 |
| MX374804B (es) * | 2008-10-14 | 2025-03-06 | Nerium Biotechnology Inc | Proceso para extraer glucósidos cardíacos y composiciones. |
| US7833829B2 (en) * | 2008-10-28 | 2010-11-16 | Honeywell International Inc. | MEMS devices and methods of assembling micro electromechanical systems (MEMS) |
| JP4761584B2 (ja) * | 2008-11-07 | 2011-08-31 | 長谷川香料株式会社 | 粘性物質の除去されたアロエ葉肉加工品の製造方法 |
| US8604187B2 (en) | 2010-01-14 | 2013-12-10 | North Texas Medical Associates | Compositions and methods of aloe polysaccharides |
| AU2011353765B2 (en) * | 2011-01-06 | 2017-04-06 | Bespoke Bioscience, Llc | Compositions and methods of aloe polysaccharides |
| KR101502219B1 (ko) * | 2013-07-03 | 2015-03-13 | 제주알로에영농조합법인 | 알로에 효소 추출물 또는 이의 분획물을 함유하는 항산화 조성물 |
| MX2016011427A (es) * | 2014-03-20 | 2016-12-02 | Morinaga Milk Industry Co Ltd | Metodo para fabricar extracto de aloe, y extracto de aloe. |
| MX372720B (es) | 2014-04-17 | 2020-05-27 | Unilever Ip Holdings B V | Extracto de aloe vera para composiciones para el cuidado personal. |
| CN106456524B (zh) * | 2014-04-17 | 2019-12-10 | 荷兰联合利华有限公司 | 个人护理组合物 |
| KR101772894B1 (ko) * | 2015-07-14 | 2017-08-31 | 코스맥스 주식회사 | 스팀 처리를 이용한 알로에 다당체의 제조방법 |
| JP6129947B2 (ja) * | 2015-12-28 | 2017-05-17 | ビスポーク バイオサイエンス，エルエルシー | アロエ多糖体の組成物及び方法 |
| US10076552B2 (en) | 2016-08-09 | 2018-09-18 | DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. | Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof |
| CN112533614A (zh) | 2018-03-28 | 2021-03-19 | 美国康宝莱国际公司 | 多糖的乙酰化 |
| JP2023533971A (ja) * | 2020-07-09 | 2023-08-07 | ユニゲン・インコーポレーテッド | 多糖類とポリフェノールを含有する免疫恒常性の調節用アロエベース組成物 |
| WO2022250313A1 (ko) * | 2021-05-27 | 2022-12-01 | 주식회사 유니베라 | 알로에 베라 꽃 추출물, 또는 알로에 베라 꽃 추출물 및 알로에 베라 다당체를 유효성분으로 함유하는 피부 보습, 재생 촉진 및 상처 치료용 조성물 |
| KR102790858B1 (ko) * | 2021-08-25 | 2025-04-07 | 주식회사 엘지생활건강 | 고분자 다당체를 포함하는 알로에 즙 |
| KR102517668B1 (ko) * | 2022-10-25 | 2023-04-05 | (주)바이텍 | 효소처리 알로에 베라를 포함하는 유산균 동결건조 보호용 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735935A (en) * | 1985-12-17 | 1988-04-05 | Carrington Laboratories, Inc. | Process for preparation of aloe products products, produced thereby and compositions thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3892853A (en) * | 1967-05-22 | 1975-07-01 | Aloe 99 & 0 Inc | Stabilized aloe vera gel and preparation of same |
| US3470109A (en) * | 1968-01-31 | 1969-09-30 | Aloe Creme Lab Inc | Method of making reconstitutable aloe gel in crystalline form |
| US4178372A (en) * | 1978-03-06 | 1979-12-11 | Coats Billy C | Hypoallergenic stabilized aloe vera gel |
| US4966892A (en) * | 1982-05-07 | 1990-10-30 | Carrington Laboratories, Inc. | Processes for preparation of aloe products products produced thereby and compositions thereof |
| US5106616A (en) * | 1988-01-14 | 1992-04-21 | Carrington Laboratories, Inc. | Administration of acemannan |
| US4917890A (en) * | 1985-06-28 | 1990-04-17 | Carrington Laboratories, Inc. | Processes for preparation of aloe products, products produced thereby and compositions thereof |
| US5118673A (en) * | 1982-05-07 | 1992-06-02 | Carrington Laboratories, Inc. | Uses of aloe products |
| US4851224A (en) * | 1986-06-05 | 1989-07-25 | Carrington Laboratories, Inc. | Process for preparation of aloe products |
| US5468737A (en) * | 1982-05-07 | 1995-11-21 | Carrington Laboratories, Inc. | Wound healing accelerated by systemic administration of polysaccharide from aloe |
| US5308838A (en) * | 1982-05-07 | 1994-05-03 | Carrington Laboratories, Inc. | Uses of aloe products |
| US5443830A (en) * | 1982-05-07 | 1995-08-22 | Carrington Laboratories, Inc. | Drink containing mucilaginous polysaccharides and its preparation |
| US4555987A (en) * | 1983-07-22 | 1985-12-03 | Tumlinson Larry N | Method and apparatus for extraction of aloe vera gel |
| US4959214A (en) * | 1985-06-28 | 1990-09-25 | Carrington Laboratories Inc. | Processes for preparation of aloe products products produced thereby and compositions thereof |
| US4957907A (en) * | 1985-06-28 | 1990-09-18 | Carrington Laboratories Inc. | Process for preparation of aloe products |
| JPS62263193A (ja) * | 1986-05-09 | 1987-11-16 | Ichimaru Pharcos Co Ltd | アロエ由来水溶性抽出物 |
| US5562906A (en) * | 1989-09-12 | 1996-10-08 | Terry; James M. | Method for the treatment of vascular disorders |
| AU2254192A (en) * | 1991-06-24 | 1993-01-25 | Carrington Laboratories, Inc. | Wound cleanser |
| US5356811A (en) * | 1992-04-21 | 1994-10-18 | Coats Billy C | Method of processing stabilized aloe vera gel obtained from the whole aloe vera leaf |
| US5512488A (en) * | 1994-05-05 | 1996-04-30 | Carrington Laboratories, Inc. | Colorimetric assay for bioactive polysaccharide |
| US5824659A (en) * | 1996-09-04 | 1998-10-20 | Board Of Regents, The University Of Texas System | Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation |
-
1998
- 1998-10-09 WO PCT/US1998/021361 patent/WO1999019505A1/en not_active Ceased
- 1998-10-09 JP JP2000516056A patent/JP4542262B2/ja not_active Expired - Fee Related
- 1998-10-09 KR KR1020067017809A patent/KR100729887B1/ko not_active Expired - Lifetime
- 1998-10-09 US US09/169,449 patent/US6133440A/en not_active Expired - Lifetime
- 1998-10-09 KR KR1020007003894A patent/KR100678238B1/ko not_active Expired - Lifetime
- 1998-10-09 EP EP98953354A patent/EP1036187A4/en not_active Withdrawn
-
1999
- 1999-04-21 US US09/295,907 patent/US6436679B1/en not_active Expired - Lifetime
- 1999-04-21 US US09/295,648 patent/US6271214B1/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735935A (en) * | 1985-12-17 | 1988-04-05 | Carrington Laboratories, Inc. | Process for preparation of aloe products products, produced thereby and compositions thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US6436679B1 (en) | 2002-08-20 |
| JP2001520019A (ja) | 2001-10-30 |
| KR20060103285A (ko) | 2006-09-28 |
| KR20010015736A (ko) | 2001-02-26 |
| EP1036187A4 (en) | 2002-03-27 |
| WO1999019505A1 (en) | 1999-04-22 |
| JP4542262B2 (ja) | 2010-09-08 |
| EP1036187A1 (en) | 2000-09-20 |
| US6271214B1 (en) | 2001-08-07 |
| KR100678238B1 (ko) | 2007-02-01 |
| US6133440A (en) | 2000-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100729887B1 (ko) | 알로에로부터 유래된 다당류를 포함하는 조성물 | |
| CA1305475C (en) | Processes for preparation of aloe products, products produced thereby and compositions thereof | |
| EP0356484B1 (en) | Process for preparation of aloe products | |
| US20030096378A1 (en) | Process for the preparation of immunomodulatory polysaccharides from aloe | |
| EP0212595B1 (de) | Calcium- und Magnesiumkomplexe von Phytohaemagglutinin-polyheteroglykanen, ihre Herstellung und pharmazeutische Zubereitungen | |
| US4762825A (en) | Polysaccharide RON substance | |
| DE2919132A1 (de) | Substanz ks-2-b, verfahren zu deren herstellung und diese substanz enthaltende mittel | |
| JPH0539305A (ja) | アストラガルス・メンブラナセウスから抽出した免疫 変調性多糖類及びこれらを含有する薬剤組成物 | |
| EP1789439B1 (en) | A purified arabinogalactan-protein (agp) composition | |
| KR102477052B1 (ko) | 선복화 단백다당체 또는 선복화 올리고당/펩타이드 복합체를 유효성분으로 함유하는 피부 외용제 조성물 및 이의 제조방법 | |
| US4442087A (en) | Interferon inducer, a process for producing the same and pharmaceutical composition containing the same | |
| DE3409029A1 (de) | Polysaccharid-rdp-substanz, verfahren zu ihrer herstellung und ihre verwendung | |
| KR20180050624A (ko) | 식물 추출물로부터 엽록소 또는 색소를 제거하는 방법 | |
| KR20180124443A (ko) | 흰목이버섯 자실체 추출물을 포함하는 피부장벽강화용 화장료 조성물 | |
| EP0173228A2 (en) | Polysaccharide rin substance, production of the same and use of the same | |
| KR102690787B1 (ko) | 고함량의 유파틸린을 함유하는 식물 추출물 및 이의 제조방법 | |
| AU2001218789B2 (en) | Polysaccharide compound having immune stimulating activity | |
| JP3254567B2 (ja) | 植物組織からの生理活性物質の製造方法及びこの物質を含有する組成物 | |
| JPH11130690A (ja) | 免疫調節薬及び抗炎症薬 | |
| CN120025466A (zh) | 一种莲花酸性多糖、其制备工艺和新用途 | |
| EP2305280A1 (en) | Bcl-2 protein expressor, apoptosis inhibitor and preventive for uv-dna damage in epidermal cells | |
| AU2001218789A1 (en) | Polysaccharide compound having immune stimulating activity | |
| JPS63233921A (ja) | 抗腫瘍活性物質及びその製造法 | |
| JPS6152806B2 (enExample) | ||
| ZA200304444B (en) | Polysaccharide compound having immune stimulating activity. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20060901 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061030 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20070327 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20070612 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20070611 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| PG1701 | Publication of correction | ||
| PR1001 | Payment of annual fee |
Payment date: 20100610 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110525 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120524 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20130527 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130527 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20140528 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140528 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20150527 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150527 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20170530 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170530 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20180529 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180529 Start annual number: 12 End annual number: 12 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20190409 Termination category: Expiration of duration |